Cyclerion Therapeutics (CYCN) Appoints Steven E. Hyman to its Board

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25. Dr. Hyman will work with Cyclerion leadership to help shape the future of its research and clinical development strategy while expanding external collaborations with scientific leaders and industry partners.

“We are delighted to welcome Dr. Steve Hyman to Cyclerion. Steve is a world-renowned leader in neuroscience with deep expertise leading large-scale, collaborative research programs aimed to discover and develop novel biomarkers and therapeutics for neuropsychiatric diseases. His experience will be instrumental as we advance our lead molecule, CY6463, and continue to build our pipeline,” said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion. “We seek board members with strong strategic judgment, an owner-oriented mindset, business savvy, a strong interest in our company, and absolute integrity, and Steve embodies all of those attributes and will serve as an outstanding representative of our shareholders and advisor to our company.”

“Despite significant advances in our understanding of the genetic and biological basis of neuropsychiatric diseases, there remains an urgent need to translate such advances into meaningful new therapies for patients. Cyclerion’s lead asset, CY6463, targets a central node of brain physiology and has the potential to address a broad range of diseases characterized by cognitive dysfunction,” said Dr. Hyman. “I look forward to working closely with Cyclerion leadership to help maximize the potential of the portfolio to address unmet patient needs.”

Dr. Hyman is a Distinguished Service Professor and the Harald McPike Professor of Stem Cell and Regenerative Biology at Harvard University and a Core Institute Member of the Broad Institute of MIT and Harvard, where he directs the Stanley Center for Psychiatric Research. Dr. Hyman also serves as Chairman of the Board of Directors of the Charles A. Dana Foundation, which supports research and education in neuroscience. In the private sector, he is founder of Emugen Therapeutics, a Director of Voyager Therapeutics and Q-State Biosciences, and serves on the scientific advisory boards of Janssen Pharmaceuticals and F-Prime Capital.

From 2001 to 2011 Dr. Hyman served as Provost of Harvard University. From 1996 to 2001, he served as Director of the National Institute of Mental Health where he emphasized investment in neuroscience and emerging genetic technologies. He has served as Editor of the Annual Review of Neuroscience (2002-2016), founding President of the International Neuroethics Society (2008-2013), President of the Society for Neuroscience (2015), and President of the American College of Neuropsychopharmacology (2018). He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine. Dr. Hyman received his B.A., summa cum laude, from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow studying History and Philosophy of Science, and an M.D., cum laude, from Harvard Medical School.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Cytek faces $56M damages award in Beckman Coulter patent case
• Sigma Lithium resumes full operations after signing TAC agreement